Four lessons from global health drug discovery: Medicine for an ailing industry?

ACS Medicinal Chemistry Letters

Volumn 3, Issue 9, 2012, Pages 688-690

  Elliott, Richard L ^a  

^a BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

COMMERCIAL PHENOMENA; DRUG INDUSTRY; DRUG RESEARCH; HEALTH; HEALTH CARE NEED; LEARNING; PRIORITY JOURNAL; REVIEW;

EID: 84866385163     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml3002105     Document Type: Review

References (4)

1. Reproduced with permission from: Scannell, J. W.; Blanckley, A.; Boldon, H.; Warrington, B. Diagnosing the decline in pharmaceutical R&D efficiency Nature Rev. Drug Discovery 2012, 11, 191-200
2. Payne, D. J.; Gwynn, M. N.; Holmes, D. J.; Pompliano, D. L. Drugs for bad bugs: Confronting the challenges of antibacterial discovery Nature Rev. Drug Discovery 2007, 6, 29-40
3. Yao, F.; MacKenzie, R. G. Obesity Drug Update: The Lost Decade? Pharmaceuticals 2010, 3, 3494-3521
4. For more information, go to www.grandchallenges.org/explorations/Pages/ introduction.aspx.